Skip to main content
Caplight Logo









Histocell

Histocell

Private
DerioHealthcare & Life Scienceshttps://histocell.com/

Last Round

Corporate Funding

Dec 12, 2022

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Histocell is a biotechnology company that develops and manufactures cell therapy products, biological medicinal products, and innovative medical devices for regenerative medicine.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

CDMOcell therapyregenerative medicineadvanced therapy medicinal productsATMPGMP manufacturingcontract manufacturingbiotech manufacturingtissue engineeringmedical devicesbiomaterialsprocess developmentbiotech outsourcingwound caredermocosmetics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Histocell Comparables

Compare Histocell with similar companies based on industry and business-model similarity.

Histocell comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stemmatters, Biotecnologia e Medicina Regenerativa S.A.
91%
Cell-Easy
86%
eXmoor Pharma
84%

Histocell Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingDec 12, 2022
Corporate FundingNov 24, 2022
VC RoundSep 14, 2018
VC RoundSep 30, 2016
VC RoundApr 1, 2015

Key People

Founding team and executive leadership

Naiara de Paz

COO - Chief Operating Officer at Histocell, Dermocosmetics brand Manager

Executive Team

Histocell Investors

Notable investors and investment history

Histocell investors
InvestorRounds
Seed Capital BizkaiaVC Round
Gestión de Capital Riesgo del País Vasco - Grupo SPRIVC Round
OrzaVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 33% MoM.

  • Jul 25, 2026

    Monthly visitors grew 202% MoM, reaching 1.7K.

Histocell Filings

Explore SEC and related filing metadata, where available.

Histocell filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Histocell's valuation, stock price, and market status.

Is Histocell a public or private company?

Histocell is a private company.

What is the current stock price of Histocell?

Histocell is a private company with no public stock price. No recent secondary market data is available.

How much is Histocell worth (valuation)?

Valuation information for Histocell is not publicly available.

Can I buy Histocell stock?

Histocell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Histocell's last funding round?

Histocell's most recent funding round was Corporate Funding on December 12, 2022.

Who are the main investors in Histocell?

Key investors in Histocell include Seed Capital Bizkaia, Gestión de Capital Riesgo del País Vasco - Grupo SPRI, Orza.

Will Histocell IPO soon?

No public IPO plans have been announced for Histocell.

How can I track Histocell secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Histocell's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDerio
Employee Range29
Year Founded2008
Last FundingDec 12, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?